Modified dendritic cells
Infection of a dendritic cell with a lentivirus impairs the dendritic cell's ability to act as an antigen presenting cell that polarizes a naïve T cell to develop along the Th1 pathway. This impairment is restored by infecting dendritic cells with lentiviruses containing vectors encoding IL-7, IL-12, and siRNA targeting IL-10 RNA.
1 . A nucleic acid comprising a first nucleotide sequence derived from a lentivirus and a second nucleotide sequence of non-lentiviral origin that encodes an agent capable of modulating a dendritic cell's ability to activate a T cell.
2 . The nucleic acid of claim 1 , wherein the second nucleotide sequence encodes IL-7.
3 . The nucleic acid of claim 1 , wherein the second nucleotide sequence encodes IL-12.
4 . A nucleic acid comprising a first nucleotide sequence derived from a lentivirus and a second nucleotide sequence of non-lentiviral origin that encodes an siRNA.
5 . The nucleic acid of claim 4 , wherein the siRNA is specific for IL-10.
6 . The nucleic acid of claim 4 , wherein the nucleic acid is comprised within a lentiviral vector.
7 . The nucleic acid of claim 6 , wherein the lentiviral vector is comprised within a virion.
8 . A dendritic cell into which has been introduced a purified nucleic acid comprising a nucleotide sequence that encodes an agent capable of modulating the dendritic cell's ability to activate a T cell.
9 . The dendritic cell of claim 8 , wherein the cell comprises a lentiviral vector.
10 . The dendritic cell of claim 8 , wherein the nucleotide sequence encodes IL-7.
11 . The dendritic cell of claim 8 , wherein the nucleotide sequence encodes IL-12.
12 . A dendritic cell into which has been introduced a purified nucleic acid comprising a nucleotide sequence that encodes an agent capable of modulating the dendritic cell's ability to activate a T cell,
wherein the nucleotide sequence encodes an siRNA.
13 . The dendritic cell of claim 12 , wherein the siRNA is specific for IL-10.
14 . The dendritic cell of claim 12 , wherein the cell comprises a lentiviral vector.
15 . A method of modulating the T cell activating activity of a dendritic cell, the method comprising the step of modulating the amount of at least one cytokine associated with the dendritic cell.
16 . The method of claim 15 , wherein the at least one cytokine is selected from the group consisting of IL-7, IL-10, and IL-12.
17 . The method of claim 16 , wherein the amount of IL-7 associated with the cell is increased.
18 . The method of claim 16 , wherein the amount of IL-12 associated with the cell is increased.
19 . A method of modulating the T cell activating activity of a dendritic cell, the method comprising the step of decreasing the amount of IL-10 associated with the dendritic cell.
20 . The method of claim 15 , wherein the step of modulating the amount of at least one cytokine associated with the dendritic cell comprises contacting the cell with a soluble cytokine.
21 . A method of modulating the T cell activating activity of a dendritic cell, the method comprising the step of modulating the amount of at least one cytokine associated with the dendritic cell,
wherein the step of modulating the amount of at least one cytokine associated with the dendritic cell comprises introducing into the dendritic cells a purified nucleic acid comprising a nucleotide sequence that encodes an agent selected from the group consisting of IL-7, IL-12, and an siRNA specific for IL-10.
22 . A nucleic acid comprising a first nucleotide sequence derived from a lentivirus and a second nucleotide sequence that encodes an siRNA.
23 . A method for modulating expression of a gene in a dendritic cell, the method comprising the step of introducing into the dendritic cell a nucleic acid comprising a first nucleotide sequence derived from a lentivirus and a second nucleotide sequence that encodes an siRNA.